About 30 million women in the U.S. have osteoporosis, with low bone mass and deteriorating bone structure that increases their risk for fractures. Racial differences in the rates of detection and management of osteoporosis were explored in a study of African American and white women published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.
[More]
Teenage girls who smoke accumulate less bone during a critical growth period and carry a higher risk of developing osteoporosis later in life, according to new research in the Journal of Adolescent Health.
[More]
A polymorphism in the vitamin D receptor gene significantly influences risk for osteoporosis, suggest results from a meta-analysis of 26 studies.
[More]
Osteoporosis, or reduced bone mineral density that can increase the risk of fractures, may affect as many as 30% of women and 12% of men worldwide. One risk factor for osteoporosis is vitamin D deficiency.
[More]
Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread (tenofovir disoproxil fumarate).
[More]
Osteoporosis Canada congratulates the Ontario government, the New Brunswick government, the Saskatchewan government and the British Columbia government for providing access to a new osteoporosis medication. Aclasta (zoledronic acid) is now available on public and private drug plans in Ontario, BC, SK, and NB meaning Canadians at high risk for fractures have access to increased treatment options.
[More]
A preliminary study of 127 post-menopausal women on hormone replacement therapy in Portugal suggests that there are several risk factors associated with osteoporosis and bone fracture these include age, low bone mineral density, a sedentary lifestyle, coffee consumption and ovariectomy. Details are reported later this month in the International Journal of Medical Engineering and Informatics.
[More]
Results from an Australian study show that men and young women with mood disorders have significantly lower bone quality than their mentally healthy counterparts.
[More]
Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.
[More]
AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.
[More]
For women of mixed racial or ethnic backgrounds, a new method for measuring bone health may improve the odds of correctly diagnosing their risk of osteoporosis and bone fractures, according to a UCLA-led study.
[More]
Georgia Health Sciences University researchers have developed a mouse that errs on the side of making bone rather than fat, which could eventually lead to better drugs to treat inflammatory diseases such as rheumatoid arthritis.
[More]
Merck, known as MSD outside the United States and Canada, today announced results from a Phase II trial for odanacatib, an investigational cathepsin K (cat-K) inhibitor in development for the treatment of osteoporosis in post-menopausal women.
[More]
Researchers at Mount Sinai School of Medicine have shown for the first time in an animal model that vitamin C actively protects against osteoporosis, a disease affecting large numbers of elderly women and men in which bones become brittle and can fracture. The findings are published in the October 8 online edition of PLoS ONE.
[More]
Five researchers were presented with 'IOF Young Investigator Awards' at the International Osteoporosis Foundation (IOF) Regionals - 2nd Middle East & Africa Osteoporosis Meeting and the 6th Pan Arab Osteoporosis Congress PAOC'6 on September 30, 2012.
[More]
Heart disease, cancer and stroke are the leading causes of death in women of all ages in the United States, according to the Centers for Disease Control and Prevention. To get ahead of these chronic health issues and possibly prevent them from worsening, experts at the University of Alabama at Birmingham urge women to get tested for key measures throughout their lives.
[More]
Abstinence from alcohol for 2 months could correct the imbalance between bone formation and resorption in alcoholic men, a study shows.
[More]
Amgen today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.
[More]
Weekly administration of oral biphosphonate alendronate could reduce loss of bone mineral density in prostate cancer patients who start androgen-deprivation therapy, show study findings.
[More]
Use of osteoporosis investigation and treatment is significantly increased in older patients with asymptomatic vertebral fracture by use of physician- and patient-targeted interventions, Canadian research suggests.
[More]